Log in to your IBTimes Account

close
ID
Password

Icahn loses campaign to change Biogen Idec board



By MARK JEWELL, AP
19 June 2008 @ 02:34 pm EST

CAMBRIDGE, Mass. - Carl Icahn lost his campaign to elect a slate of dissident nominees to Biogen Idec Inc.'s board on Thursday, an effort the activist investor hoped would eventually trigger a sale of the 30-year biotechnology firm to a major pharmaceutical company.


Biogen
REUTERS/Brian Snyder (UNITED STATES)
1 of 1

Related Topic

Get stories by e-mail on this topic.

E-mail:
Quotes
BIIB 49.34 -1.16

SYMBOL LOOKUP

Despite shareholders' election of four company-backed nominees rather than Icahn's three candidates, one of the billionaire's nominees said afterward that Biogen Idec's management had agreed to meet with him to discuss ways of improving the company's prospects, including strengthening drug research and employee morale.

"We have heard from major shareholders and employees who think that things can be done better at Biogen," said Alexander Denner, managing director of Icahn's investment firm, Icahn Partners.

At the start of Biogen Idec's annual shareholder meeting in Cambridge, Denner conceded that Icahn had failed to win enough support to elect his three nominees--a result that had been widely expected after four firms that advise shareholders on proxy ballots recently backed the company's nominees.

Without releasing vote totals, the Cambridge-based company said its nominees--Stelios Papadopoulos, Cecil Pickett, Lynn Schenk, and Phillip Sharp--had won the four open seats on the company's 12-member board. A vote tally is expected in about two weeks.

Denner declined to say how much support Icahn had lined up for dissident nominees Anne Young, a Harvard Medical School neurology professor; Richard Mulligan, a Harvard genetics professor; and Denner. He did say that one of Biogen's 10 largest shareholders--he wouldn't say which one--offered support.

Icahn was not among the about 100 people attending the meeting. One of them, Donald Sohn, a longtime holder of thousands of Biogen shares, said Icahn didn't help his cause by staying away.

"It would have been a courtesy if he had at least showed up," said Sohn.

Another shareholder, John Kalisz, said the scientific expertise that Icahn's Harvard-affiliated nominees could bring to Biogen could help it. But Kalisz disliked Icahn's strategy of investing in companies he thinks are undervalued, then using the holdings as leverage to try to bring about management changes or buyouts that bring hefty premiums to shareholders.

"If he's just wishing to make a quick dollar and chopping things up just for his pockets, boy, that doesn't make sense," said Kalisz, of New Bedford.

Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

    Click!
  • Rate this article:

Comments

Post Your Comment

You must be an IBTimes member to post a comment. Login | Register


advertisement
More Industries
A Keefe, Bruyette & Woods analyst Monday set a lower profit estimate on American International Group Inc. after the insurer said it plans to shed busines...
Aerospace supplier Goodrich Corp. said Monday it will supply air data systems and crew seats for Brazil's big manufacturer of executive jets and midsize ...
Salix Pharmaceuticals Ltd. said Monday its drug candidate rifaximin met its goals in a midstage clinical trial, improving quality of life for patients wi...

Advertisement
Corporate Website Design

Professional Website Design For Corporate - Get a Free Quote Today

advertisement
 
IBTimes.com Web
Partners
International Business Times© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives